<SEC-DOCUMENT>0001075880-13-000005.txt : 20130205
<SEC-HEADER>0001075880-13-000005.hdr.sgml : 20130205
<ACCEPTANCE-DATETIME>20130204204229
ACCESSION NUMBER:		0001075880-13-000005
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20130204
FILED AS OF DATE:		20130205
DATE AS OF CHANGE:		20130204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13571783

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>patentannouncement.htm
<TEXT>
<HTML>
<head><title>Converted by EDGARwiz</title> </head> <body style="MARGIN-TOP:0px; FONT-SIZE:10pt; COLOR:#000000; FONT-FAMILY:Times New Roman"> <div style=WIDTH:553px> <p style=MARGIN:0px><br></p> <p style="MARGIN-TOP:0px; MARGIN-BOTTOM:16px" align=justify>&nbsp;</p> <p style="FONT-SIZE:11pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify><b>5 February 2013</b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify><b>ASX RELEASE</b><font style=FONT-SIZE:16pt><b> </b></font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify><b>Novogen</b><b> Announces Filing of Key Patent</b><b> Application</b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>Novogen is pleased to announce the filing of a provisional patent application covering the novel technology associated with the manufacture and use of it new class of molecules referred to as <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#145;</font><i>super-</i><i>benzopyrans</i><i><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font></i>. </p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>The invention is based on technology that Novogen acquired when it purchased Triaxial Pharmaceuticals Pty Ltd on 7 Dec 2012. Triaxial had developed a novel manufacturing process that involved chemically <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#145;</font>bending<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font> molecules to allow the insertion of atoms not previously possible. The Triaxial goal was the ability to design and build molecules to suit particular therapeutic applications. The initial result of this technology was the creation of an entirely new family of compounds known as super-benzopyrans, hitherto impossible to manufacture by existing techniques, and displaying a range of anti-cancer functions not previously experienced.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>In the 2 months since the merger, Novogen has been conducting a series of manufacturing studies designed to strengthen its patent position through <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#145;</font>reduction to practice<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>, a key requirement for sound patent protection. These studies have focused on the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s inaugural drug candidate, CS-6, with the manufacturing process now in place and able to produce the quantities of drug required for its developmental program.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>Provisional patent application No 2012905600 covers the three cornerstones of patent protection around Novogen<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s initial family of super-benzopyrans: method of manufacture, method of use, and composition of matter. </p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>Dr Andrew Heaton, Novogen Chief Scientist, said, <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font> the design and manufacturing technology that is the basis of the Novogen technology, in our view heralds a new era in drug discovery, and not just in the oncology field.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>He added, <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>the ability to create a potent anti-cancer drug such as CS-6, and to then add a further layer of design to improve its ability to attack cancer cells, and then to add a further design layer to increase the likelihood of it being able to cross the blood-brain barrier, is a practical example of what is achievable with this technology.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>Professor Graham Kelly, Novogen CEO, said, <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>lodging this patent application marks two milestones. The first is our overriding efforts to protect our valuable intellectual property. The second is that we have achieved the means to manufacture CS-6 economically and efficiently, something that is essential to our objective of taking CS-6 into humans with primary brain cancer in 2014. </p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify><b>About </b><b>Novogen</b></p> <p style="MARGIN-TOP:0px; FONT-SIZE:12pt; MARGIN-BOTTOM:30px; LINE-HEIGHT:15.75pt; FONT-FAMILY:Cambria,Times New Roman" align=justify><font style=BACKGROUND-COLOR:#ffffff>Novogen</font><font style=BACKGROUND-COLOR:#ffffff> Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#145;</font>NRT<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>) and NASDAQ (symbol <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#145;</font>NVGN<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>). &nbsp;The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on super-</font><font style=BACKGROUND-COLOR:#ffffff>benzopyr</font><font style=BACKGROUND-COLOR:#ffffff>an</font><font style=BACKGROUND-COLOR:#ffffff> and <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#145;</font>stealth<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font> drug technologies</font><font style=BACKGROUND-COLOR:#ffffff>. The Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s inaugural drug candidate is CS-6.</font></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify><b>About CS-6</b></p> <p style="MARGIN-TOP:0px; FONT-SIZE:12pt; MARGIN-BOTTOM:30px; LINE-HEIGHT:15.75pt; FONT-FAMILY:Cambria,Times New Roman" align=justify><font style=BACKGROUND-COLOR:#ffffff>CS-6 belongs to a new class of drug candidates known (structurally) as super-</font><font style=BACKGROUND-COLOR:#ffffff>benzopyrans</font><font style=BACKGROUND-COLOR:#ffffff> </font><font style=BACKGROUND-COLOR:#ffffff>displaying potent anti-cancer activity </font><font style=BACKGROUND-COLOR:#ffffff>and demonstrating increased bio-availability to cancer cells (<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#145;</font>stealth<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font> technology). CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells, with particular activity against human </font><font style=BACKGROUND-COLOR:#ffffff>glioblastoma</font><font style=BACKGROUND-COLOR:#ffffff> cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of </font><font style=BACKGROUND-COLOR:#ffffff>glioblastoma</font><font style=BACKGROUND-COLOR:#ffffff> </font><font style=BACKGROUND-COLOR:#ffffff>multiforme</font><font style=BACKGROUND-COLOR:#ffffff>, the main form of primary brain cancer.</font></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify><b>Further information</b></p> <p style="MARGIN-TOP:0px; FONT-SIZE:12pt; MARGIN-BOTTOM:30px; LINE-HEIGHT:15.75pt; FONT-FAMILY:Cambria,Times New Roman" align=justify><font style=BACKGROUND-COLOR:#ffffff>Contact Dr Graham Kelly, Chief Executive Officer.</font></p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>T: &nbsp;(61 2) 9878 0088</p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>M: (61) 0459 200 095</p> <p style="FONT-SIZE:12pt; MARGIN:0px; FONT-FAMILY:Cambria,Times New Roman" align=justify>E: <u>Graham.Kelly@novogen.com</u></p> <p style=MARGIN:0px align=justify><br></p> <p style="MARGIN-TOP:0px; FONT-SIZE:12pt; MARGIN-BOTTOM:30px; LINE-HEIGHT:15.75pt; FONT-FAMILY:Cambria,Times New Roman" align=justify><font style=BACKGROUND-COLOR:#ffffff>Further information is available on the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s web site, </font><font style=BACKGROUND-COLOR:#ffffff><u>www.novogen.com</u></font></p> <p style="MARGIN-TOP:0px; MARGIN-BOTTOM:25px; LINE-HEIGHT:15.75pt"><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br><br></p> <p style=MARGIN:0px><br></p></div></body>
<!-- EDGAR Validation Code: 3DB60D77 -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
